Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday

Verve Therapeutics (NASDAQ:VERV) is projected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Verve Therapeutics to post earnings of ($0.72) per share for the quarter.

Verve Therapeutics Stock Down 7.0 %

VERV stock opened at $7.28 on Monday. The business’s fifty day moving average is $6.80 and its 200-day moving average is $5.96. The company has a market cap of $616.32 million, a P/E ratio of -2.96 and a beta of 1.74. Verve Therapeutics has a twelve month low of $4.30 and a twelve month high of $19.34.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on VERV shares. William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a report on Friday. Royal Bank of Canada lowered their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. HC Wainwright lowered their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their target price on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.